<DOC>
	<DOCNO>NCT02713893</DOCNO>
	<brief_summary>The primary objective study evaluate local tolerability new Econazole/Benzydamine product , comparison Econazole Benzydamine stand-alone product placebo . Pharmacokinetics study product single repeat application day 15 day , safety investigational product comfort use also evaluate secondary objective .</brief_summary>
	<brief_title>Tolerability Pharmacokinetic Study Econazole Nitrate Benzydamine HCl Intravaginal Cream</brief_title>
	<detailed_description />
	<mesh_term>Benzydamine</mesh_term>
	<mesh_term>Econazole</mesh_term>
	<criteria>1 . Informed consent : sign write informed consent inclusion study ; 2 . Sex age : female , age 1855 year old inclusive ; 3 . Body Mass Index ( BMI ) : 18.530 kg/m2 inclusive ; 4 . Vital sign : systolic blood pressure 100139 mmHg , diastolic blood pressure 5089 mmHg , heart rate 5090 bpm , measure 5 min rest ( sit position ) ; 5 . Full comprehension : ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate investigator comply requirement entire study ; 6 . Sexual abstinence : agreement sexual abstinence study ; 7 . Contraception fertility : woman childbearing potential , even sexual abstinent study require study inclusion criterion , must use least one reliable method contraception , follow : 1. hormonal oral , implantable , transdermal , injectable contraceptive least 2 month screen visit ; 2. nonhormonal intrauterine device [ IUD ] least 2 month screen visit ; 3. male sexual partner agree use male condom ; 4. vasectomise sexual partner . Female participant nonchildbearing potential admit . For female subject , pregnancy test result must negative screen scheduled evaluation ; 8 . PAP test : negative result PAP test ( i.e . normal PAP test result without atypical cell ) screen . 1 . ECG ( 12leads , supine position ) : clinically significant abnormality ; 2 . Physical finding : clinically significant abnormal physical finding could interfere objective study judged investigator ; 3 . Laboratory analysis : clinically significant abnormal laboratory value indicative physical illness ; 4 . Allergy : ascertain presumptive hypersensitivity ( include allergy ) active ingredient ( econazole and/ benzydamine ) and/or formulation ' excipients related drug , e.g . azoles ; history anaphylaxis drug allergic reaction general , investigator considers may affect outcome study ; 5 . Diseases : relevant history renal , hepatic , gastrointestinal , genitourinary , cardiovascular , respiratory , skin , haematological , endocrine neurological disease may interfere aim study affect subject 's safety ; 6 . Genitourinary disease : presence specific genitourinary symptom detect Visit 2 relevant questionnaire ( genitourinary symptom questionnaire ) ; 7 . Infection history : history bacterial urinary tract bacterial fungal vaginal infection 3 week screen visit ; 8 . Infections : bacterial fungal infection ( microbiology assessment ) ; 9 . Gynaecological finding : clinically significant abnormal finding gynaecological visit perform study gynaecologist ; 10 . Mucosa condition : alter mucosa condition affect site application ( e.g . open lesion ) ; 11 . Vaginal condition : use vaginal detergent , soap wash , investigator 's opinion , may influence vaginal pH and/or change vaginal flora ; 12 . Medications : medication ( topical systemic ) , include counter , herbal medication , topical drug application area anticoagulant , warfarin acenocoumarol , 2 week start study . Hormonal contraceptives hormonal replacement therapy allow . Paracetamol allow countermeasure adverse event , case case basis , deem appropriate investigator ; 13 . Investigative drug study : participation evaluation drug 3 month study , calculate first day month follow last visit previous study first day present study ( date inform consent signature ) ; 14 . Blood donation : blood donation 3 month study ; 15 . Drug , alcohol , caffeine , tobacco : history drug , alcohol ( &gt; 1 drink/day , define accord USDA Dietary Guidelines 2010 ) , tobacco ( â‰¥ 10 cigarettes/day ) caffeine ( &gt; 5 cup coffee/tea/day ) abuse ; 16 . Diet : Abnormal diet ( &lt; 1600 &gt; 3500 kcal/day ) substantial change eat habit 4 week study ; vegetarian 17 . Pregnancy : positive miss pregnancy test screen day 1 , pregnant lactate woman female childbearing potential follow adequate contraceptive procedure ; 18 . Noncompliance : subject suspect high potential noncompliance study procedure accord investigator 's judgement , include noncompliance sexual abstinence study ; 19 . Drug test ( cocaine , amphetamine , methamphetamine , cannabinoids , opiates ecstasy ) : positive result drug test screen 20 . Alcohol test : positive alcohol breath test day 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Econazole nitrate 1 %</keyword>
	<keyword>Benzydamine HCl 0.12 %</keyword>
	<keyword>Intravaginal cream</keyword>
	<keyword>Antimycotic</keyword>
	<keyword>Tolerability</keyword>
</DOC>